Dir
Paul L. Berns is a biopharmaceutical executive and investor who serves as a director of Kardigan, Inc. (KARD), where he brings more than three decades of operating and board experience in specialty pharma and therapeutics.[[2]](https://neumoratx.com/our-team/paul-berns/)[[7]](https://www.kardigan.bio/leadership/)[[8]](http://openinsider.com/insider/Berns-Paul-L/1202769) He is best known as the co‑founder, chairman, and chief executive officer of Neumora Therapeutics, a company developing targeted medicines for brain diseases, and as a Managing Director at ARCH Venture Partners, focusing on early-stage life science investments.[[1]](https://www.marketscreener.com/insider/PAUL-BERNS-A04764/)[[2]](https://neumoratx.com/our-team/paul-berns/)[[4]](https://www.vcsheet.com/who/paul-berns)[[9]](https://www.zoominfo.com/p/Paul-Berns/1493671556) Berns has also held numerous board roles across innovative biotech companies and currently sits on the boards of Mirador Therapeutics, Kardigan, Rhygaze, Epirium, and several other private and public life sciences companies.[[2]](https://neumoratx.com/our-team/paul-berns/)[[4]](https://www.vcsheet.com/who/paul-berns)
Earlier in his career, Berns held multiple CEO roles at publicly traded biopharmaceutical companies, including Anacor Pharmaceuticals (2014–2016), Allos Therapeutics (2006–2012), and Bone Care International (2002–2005), each of which was acquired by larger pharmaceutical companies (Pfizer, Spectrum Pharmaceuticals, and Genzyme, respectively).[[2]](https://neumoratx.com/our-team/paul-berns/)[[3]](https://mauiderm.com/faculty-bio-berns/) Before these leadership positions, he served as Vice President and General Manager of the Immunology, Oncology, and Pain Therapeutics business unit at Abbott Laboratories, Vice President of Marketing at BASF Pharmaceuticals/Knoll, and held various management roles at Bristol‑Myers Squibb from 1990 to 2000.[[2]](https://neumoratx.com/our-team/paul-berns/)[[3]](https://mauiderm.com/faculty-bio-berns/) Berns co‑founded and/or chaired multiple therapeutics companies, including HI-Bio (acquired by Biogen in 2024) and Metsera Therapeutics (acquired by Pfizer in 2025), and he holds a B.S. in Economics from the University of Wisconsin.[[1]](https://www.marketscreener.com/insider/PAUL-BERNS-A04764/)[[2]](https://neumoratx.com/our-team/paul-berns/)[[3]](https://mauiderm.com/faculty-bio-berns/)
View full insider profile →
Discussion